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TreatmentAbstract Background and aims: Currently, there is no widely accepted evidence-based pharmaco-
therapy regime for the treatment of psychostimulant dependence. Yet, different pharmacological
approaches have been tried in the treatment of MA addiction. The present study was conducted
to compare efﬁciency of methylphenidate which is relatively easily accessible in our country, with
resperidone for this purpose.
Methods: Eighty-six patients with MA dependence according to criteria deﬁned by DSM IV-TR
were divided into two groups. Patients in group R were given oral resperidone 1 mg daily for
1 week; then 2 mg daily in a divided dose for 3 weeks. Patients in group M were given oral meth-
ylphenidate 10 mg daily for 2 weeks, 7.5 mg daily for 1 week, then 5 mg daily for 1 week. They were
evaluated for drug craving, psychological, neurologic and somatic symptoms at the start and end of
the study.
Findings: Both drugs were useful for lowering drug craving in patients; however resperidone was
more effective (6.31 ± 8.31 vs.19.6 ± 12.45 cravings per week, respectively). The effects of resperi-
done were more notable in lowering frequency and intensity of psychiatric, neurologic, cardiac and
somatic symptoms of the patients after discontinuation of MA abuse; however methylphenidate
was effective too; though with a lower potency.
Conclusion: The present study conﬁrmed that both methylphenidate and resperidone can suc-
cessfully be used for treatment of MA dependence, in order to reduce drug craving and psycholog-
ical, neurologic, and somatic problems in patients. However, the efﬁcacy of methylphenidate was
estimated to be less than that of resperidone for this purpose.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The term ‘‘amphetamines’’ refers to a range of drugs related to
amphetamine which share stimulant properties. Ampheta-
mines can include amphetamine, methamphetamine,
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stasy’’), methcathinone, and ephedrine. They are now the ma-
jor illicit amphetamines available worldwide (Singleton et al.,
2009). Methamphetamine (MA) is an indirect sympathomi-
metic agent that is distinguished from amphetamine by a more
rapid distribution into the central nervous system (CNS),
resulting in a rapid onset of euphoria that is the desired effect
on those abusing the drug (Vearrier et al., 2012). Methamphet-
amine was ﬁrst synthesized from ephedrine in 1893 by the Jap-
anese scientist Nagai Nagayoshi, 6 years after the discovery of
amphetamine (Panenka et al., 2012).
In several East Asian countries, methamphetamine is the
most commonly used illicit drug, with recent data suggesting
expanding markets in South Africa, Iraq and the Middle East.
In Czech Republic and Slovakia, methamphetamine is the
most commonly injected drug. Recent data from research stud-
ies suggest an increase in (injecting) the use of methamphet-
amine in Ukraine, Georgia, Armenia, and the Russian
Federation (Singleton et al., 2009). The same trend has devel-
oped in Iran. An illicit drug with street name ‘‘Shisheh’’ has
been dispensed among drug abusers in Iran whose main con-
stituent is methamphetamine (Kazemifar et al., 2011). Its
abuse has been recently popular in Iran with some dream like
propaganda about its effect as a non-addictive drug (Kazemi-
far et al., 2011).
Methamphetamine abuse is a serious public health problem
because of both costs associated with treatment of metham-
phetamine associated adverse health effects and crime and vio-
lence perpetrated to obtain methamphetamine or because of
methamphetamine-related aggressive behavior (Vearrier
et al., 2012).
Amphetamine dependence is characterized by an increased
tolerance to the drug, withdrawal symptoms (sleep and appetite
disturbances, fatigue, depression, irritability, craving, depres-
sion, anxiety or agitation), and inability to reduce drug use de-
spite signiﬁcant negative social, health and psychological
problems associated with such use; as stated in DSM IV TR
(Pe´rez-Man˜a´ et al., 2012). There is currently no widely accepted
evidence-based pharmacotherapy regime for the treatment of
psychostimulant dependence (Schifano 2011; Srisurapanont
et al., 2001). However, different pharmacological approaches
have been tried in the treatment of MA addiction. The most
conventional drugs include antidepressants, antipsychotics
and substitution/replacement therapies. The critical role of
dopamine neurotransmission in the psychostimulant and
addictive properties of MA and other amphetamines has driven
research on the efﬁcacy of dopamine D2 receptor antagonists
(i.e., antipsychotics) as potential treatments for stimulant abuse
(Panenka et al., 2012). Opioid antagonists or agonists have also
been suggested for drug therapy in MA dependence or other
stimulants (Mooney et al., 2013; Penetar, 2012).
The prescription stimulant methylphenidate also exhibits
potential for the treatment of MA addiction. The use of psy-
chostimulants to treat amphetamine dependence or abuse is
based on previous successful results of replacement therapy
in other disorders such as nicotine or opiate dependence (Pe´r-
ez-Man˜a´ et al., 2012). By deﬁnition, medications used as main-
tenance therapy should have similar properties (mechanism of
action, behavioral effects) to the abused drug, but less addic-
tive potential. Psychostimulants may substitute the use of
amphetamines by reducing amphetamine withdrawal and crav-
ing and therefore, leading to abstinence (Pe´rez-Man˜a´ et al.,2012; White, 2000). Case studies of amphetamine dependence
in subjects without psychiatric comorbidity have reported that
methylphenidate provided long-term help for MA use (Pane-
nka et al., 2012).
The present study was conducted to evaluate the efﬁcacy of
methylphenidate as a prescribed drug for treatment of MA
dependence and compare it with resperidone an atypical anti-
psychotic which is also a candidate for treatment of MA
dependence.
2. Materials and methods
The studied individuals were randomly selected from persons
with MA dependence according to criteria deﬁned by DSM
IV-TR who had referred to a rehabilitation clinic in a univer-
sity teaching hospital, Arak city, Iran in 2012. The other inclu-
sion criteria were positive urine test for MA, negative history
of abuse of other drugs and alcohol, and age between 18–
65 years. If any patient had history of any major organic dis-
eases, use of antipsychotic or mood changing drugs, any men-
tal illnesses, suicidal ideation, pregnancy or lactation, and
sensitivity to methylphenidate or resperidone, he/she was ex-
cluded from the study. All the studied patients provided in-
formed consent for participation to the study. The study had
been approved by local ethical committee of Arak’s university
of medical sciences. It was registered in database of Iranian
clinical trials (reg. no.: IRCT201202159018N1).
86 patients were enrolled into the study. They were ran-
domly divided into two groups with equal size. The patients
in the ﬁrst group were given oral resperidone 1 mg daily for
1 week; then 2 mg daily in a divided dose for 3 weeks. The pa-
tients in the second group were given oral methylphenidate
10 mg daily for 2 weeks, 7.5 mg daily for 1 week, then 5 mg
daily for 1 week.
The patients were visited by a physician every week. They
were evaluated for drug craving, psychological, neurologic
and somatic symptoms at the start and end of the study.
The collected data were analyzed by SPSS software version
16.0. Differences between the groups were determined by
T-test and chi-square test. Statistical signiﬁcance was set at
p-value less than 0.05.3. Results
73 Patients including 35 in methylphenidate group (group M)
and 38 in resperidone group (group R) completed their treat-
ment course. The remaining 13 (eight in group M and ﬁve in
group R) were excluded due to failure to follow the recom-
mended treatment regime. General characteristics of the
groups are shown in Table 1. All of the patients were smoking
the drug. No oral or injection route for use of the drug was
seen. 31 patients (14 in group M and 17 in group R) had no
previous attempts for treatment of their abuse.
Patients in group M had weight gain during the study
(2.40 ± 1.037 kg). Patients in the other group had weight gain
too (2.47 ± 1.042 kg). Their difference was not statistically sig-
niﬁcant (p-value = 0.9). A comparison of groups for drug
craving before and after the study is shown in Table 2. The dif-
ference between groups was not statistically signiﬁcant before
the study (p-value = 0.6); but was notable after the end of
the study (p-value = 0.002).
Table 2 The drug craving in studied group before and after
the study.
Drug craving (number of cravings per week)
Before the study At the end of the study
Group R 38.43 ± 24.38 6.31 ± 8.31
Group M 41.33 ± 23.32 19.6 ± 12.45
Table 1 General characteristics of the studied groups.
Group M n= 35 Group R n= 38 p-Value
Age 34.12 ± 7.27 30.35 ± 7.68 0.20
Sex:
Male 32 32 0.31
Female 3 6
Blood pressure:
Systolic 123 ± 10.11 132 ± 10.98 0.34
Diastolic 83 ± 8.75 86 ± 8.65 0.31
Pulse rate 87 ± 8.55 90 ± 8.78 0.25
Respiratory rate 18 ± 1.2 19 ± 1.3 0.21
Body temperature (centigrade) 37.1 ± 0.32 37.0 ± 0.34 0.30
Body weight (kg) 65.3 ± 13.06 64.8 ± 13.89 0.20
Daily dose of the drug (grams) 1.27 ± 0.86 1.24 ± 0.77 0.18
Frequency of drug use per day 5.93 ± 3.72 5.88 ± 3.64 0.22
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nervousness, panic attack, visual or tactile hallucination, delu-
sion, suicidal ideation or attempt, obsessive thoughts or acts,
increased daily activities, irritability, excitability, verbalism,
insomnia, and anxiety was evaluated in patients. Severity of
complaints had been scored from 0–5, as judged by the exam-
ining physician. The result is demonstrated in Table 3. The
difference between groups was statistically signiﬁcant
(p-value = 0.0001).
Presence and severity of neurologic problems including tre-
mor, convulsion, dizziness, altered level of consciousness, ath-
etotic movements, speech disorders, and numbness in
extremities were evaluated in the studied patients by physician
and were scored from 0–5. The scores were 33.17 ± 6.72 and
33.27 ± 6.78 in groups R and M, respectively before the study;
which changed to 19.73 ± 3.50 and 28.47 ± 5.60 correspond-
ingly at the end of the study. The changes were statistically
signiﬁcant (p-value = 0.0001).
Patients were evaluated for cardiovascular related problems
consisting of dyspnea, chest pain, hypertension, tachycardia,Table 3 Severity of psychiatric symptoms and signs in studied
group before and after the study.
Degree of severity of psychiatric symptoms and signs
Before the study At the end of the study
Group R 58.33 ± 9.24 35.73 ± 5.90
Group M 58.80 ± 13.47 52.6 ± 12.80and palpitation. Each problem would be scored from 0–5 by
a physician; if present. The scores were 11.13 ± 5.14 and
12.37 ± 4.39 in groups R and M respectively before the study;
which changed to 7.83 ± 3.30 and 10.80 ± 3.49 in that order
at the end of the study. The difference between groups was sta-
tistically signiﬁcant (p-value = 0.001).
The presence of somatic symptoms including midriasis,
xerostomia, pruritus, acne, any other skin lesion, change in
appetite, and alteration in body temperature was also assessed
in patients. They were scored from 0 to 5 by the examining
physician. The scores of the patients were 19.37 ± 5.69 and
19.40 ± 7.79 in groups R and M, respectively before the study.
The scores were 13.47 ± 5.07 and 17.97 ± 7.35 in the groups
R and M, respectively at the end of the study. The difference
between groups was statistically signiﬁcant after the end of
the study (p-value = 0.008).
4. Discussion
The present study conﬁrmed that both methylphenidate and
resperidone can successfully be used for treatment of MA
dependence, in order to reduce drug craving and psychologi-
cal, neurologic, and somatic problems in patients. However,
the efﬁcacy of resperidone was estimated to be higher than that
of methylphenidate for this purpose.
Indirect evidence supports a rationale for the use of antide-
pressants – particularly those with a serotonergic mechanism
of action, based on efﬁcacy in preclinical models, clinical efﬁ-
cacy in treating compulsive behavior, and potential for amelio-
rating the affective symptoms of stimulant withdrawal.
However, most studies with antidepressants have not found
clinically meaningful beneﬁts of these drugs on a range of
MA abuse-related measures, including drug craving (Panenka
et al., 2012; Shoptaw et al., 2006). Heinzerling and his col-
leagues have reported discouraging results in their study con-
ducted to evaluate the efﬁcacy of Bupropion for treatment of
MA dependence in adolescents (Heinzerling et al., 2013),
though it had been recommended for MA dependence with
moderate drug use in an earlier study (Brensilver et al., 2012).
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therapy for stimulant dependence remains elusive; with a noted
lack of controlled clinical trials studying methamphetamine
abuse in particular (Ma et al., 2012).
The dysregulation of dopamine (DA) transmission has been
a focus of studies on mechanisms of addiction. However, cap-
italizing on this knowledge has not yet produced effective
pharmacotherapies (Graves et al., 2012). There is also evidence
to suggest contributions of glutamatergic neurotransmission to
MA taking and relapse behaviors (Kufahl et al., 2013), how-
ever its clinical implications remain to be determined.
Non-amphetamine psychostimulants such as modaﬁnil
have been studied for treatment of MA dependence too; with
promising results (Anderson et al., 2012).
Due to lack of a hopeful drug effective in the treatment of
MA dependence, the present study was conducted to compare
the efﬁciency of methylphenidate which is relatively easily
accessible in our country, with that of resperidone for this
purpose.
There are few related published studies to be compared.
Laqueille and his coworkers have reported 4 cases of MA
dependence treated with methylphenidate, however all four
were 50–60 years old (Laqueille et al., 2005). Tiihonen and
his colleagues have compared methylphenidate with ari-
piperazol for treatment of MA dependence, however their
study has ended prematurely and all of their patients were
IV abuser; yet their results have been promising (Tiihonen
et al., 2007).
Similarly, the current study conﬁrmed that methylpheni-
date is a relatively effectual drug for treatment of psychiatric,
neurologic, and somatic signs and symptoms after discontinu-
ation of MA abuse and decline in drug craving; in comparison
with currently recommended drugs, such as resperidone.
The starting dose of methylphenidate was 10 mg per day.
Possibly, the use of a higher dosage to overcome cross-toler-
ance between MA and methylphenidate will lead to more effec-
tive results. It can be examined in future studies.
In summary, results of the present study showed that meth-
ylphenidate can be used in treatment of MA dependence; how-
ever its effect seems to be less than that of resperidone.
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